VIEW ALL RESEARCH-GROUP

Susceptibility, tumor progression and resistance
Pujana’s Lab

DESCRIPTION

Targeting cancer complexity at origin and progression

Our research is focused on better understanding breast cancer initiation and, from acquired knowledge, to assess targeted prevention strategies. In parallel, we study pan-cancer vulnerabilities and the connection to a rare, lung metastatic disease, lymphangioleiomyomatosis (LAM).

Miquel Angel Pujana

Group leaders

Principal investigator

Francesca Mateo

Researchers

Research assistant

Roderic Espín

Young investigators

PhD student

Lara Ruiz

Young investigators

PhD student

Arzoo Shabbir

Young investigators

PhD student

Luís Alfaro

Young investigators

PhD student

Aneuploidy selects for the acquisition of driver genes in breast cancer

/in /by

Nature. 2026 Jul 8. doi: 10.1038/s41586-026-10752-9. Online ahead of print. ABSTRACT Chromosome instability is highly prevalent in cancer and drives large-scale chromosomal imbalances, known as aneuploidies1-4. How aneuploidy contributes to tumorigenesis remains difficult to study due to the vast numbers of genes affected. Here we established a CRISPR knockout- and activation-linked assay (CRISPR-KOALA), enabling high-throughput […]

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis

/in /by

ERJ Open Res. 2026 Jun 29;12(3):01285-2025. doi: 10.1183/23120541.01285-2025. eCollection 2026 May. ABSTRACT BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare, low-grade neoplasm that causes progressive cystic lung destruction and is often associated with renal angiomyolipomas (AMLs). Given evidence of pleiotropy linking LAM risk to pulmonary traits, we investigated whether glucocorticoid receptor (GR) signalling might influence LAM biology […]

Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study

/in /by

Pol Arch Intern Med. 2026 Jun 12:17320. doi: 10.20452/pamw.17320. Online ahead of print. ABSTRACT INTRODUCTION: Sirolimus is the standard disease-modifying therapy for lymphangioleiomyomatosis (LAM), but long-term routine-care data integrating pulmonary, lymphatic, extrapulmonary, and biomarker outcomes remain limited. OBJECTIVES: To assess long-term effectiveness and safety of sirolimus in routine clinical practice. PATIENTS AND METHODS: We retrospectively […]

Advancing Cancer Prevention through Precision Prediction

/in /by

Cancer Discov. 2026 Apr 1;16(4):647-650. doi: 10.1158/2159-8290.CD-25-2235. ABSTRACT Emerging knowledge, integrative frameworks, and multidisciplinary partnerships together create an unprecedented opportunity to advance cancer prevention through precision. By combining multimodal risk assessment with causal biological insight and dynamic models of early carcinogenesis, precision prevention can enable actionable, equitable, and acceptable preventive and interception strategies. PMID:41918357 | […]

A rise in double-strand breaks sensitizes tumors to oxidative metabolism inhibitors

/in /by

Biomed Pharmacother. 2026 Mar 10;197:119184. doi: 10.1016/j.biopha.2026.119184. Online ahead of print. ABSTRACT Double-strand breaks (DSBs) accumulate in tumoral DNA due to deficiencies in homologous recombination (HR) repair, such as mutations in BRCA genes, or following antitumoral treatments. In the present study, we show that DSB accumulation, irrespective of origin, triggers an adaptive shift toward oxidative […]

The group works and collaborates to decipher the systems mechanisms of cancer development and progression, with the aim of developing more precise preventive and therapeutic approaches. The group combines in silico and wet-lab studies for the purpose of identifying cancer principles and vulnerabilities.

CIMBA – Consortium of Investigators of Modifiers of BRCA1/2

https://cimba.ccge.medschl.cam.ac.uk/

Lobular Breast Cancer

https://lobsterpot.eu/

BRCA1 breast cancer

Khokha Lab

https://medbio.utoronto.ca/faculty/khokha

Hakem Lab

https://medbio.utoronto.ca/faculty/hakem

Maxwell Lab

https://www.bcchr.ca/cmaxwell

Serra Lab

https://vhio.net/biosketch-violeta-serra/

Cancer biology

Schramek Lab

https://schramek.lunenfeld.ca/

Li Lab

https://lilab.smhs.gwu.edu/

Barcellos-Hoff Lab

https://barcelloshofflab.ucsf.edu/principal-investigator

Cancer genetics

De Cid Lab – GCAT

http://www.gcatbiobank.org/

LAM research

Johnson Lab – LAM UK

https://www.nottingham.ac.uk/medicine/people/simon.johnson

Elżbieta Radzikowska

National Tuberculosis and Lung Diseases Research Institute, Poland

Kwiatkowski Lab

https://www.kwiatkowskilab.org/

AELAM

https://www.aelam.org/

VHIR

https://vhir.vallhebron.com/en/research/pneumology

Molina Lab

https://idibell.cat/en/research/translational-medicine-area/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program/pneumology/

Research group photo.Pujana's Lab
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

Belver’s LabBelver's LabMenendez's LabMenendez’s Lab